Oligometastatic Disease — Limited Cancer Spread

Oligometastatic disease is defined as an intermediate biological state between purely localised cancer and widespread, multi-organ metastatic dissemination. While precise thresholds vary slightly among clinical guidelines, it is generally characterised by the presence of one to five metastatic lesions, typically across a limited number of organs.

Biologically, tumours in this state possess limited metastatic capacity, meaning the secondary lesions may not yet have acquired the molecular machinery necessary for rapid, widespread seeding. Distinctions are made between synchronous oligometastases (detected at initial diagnosis) and metachronous oligometastases (developing after a disease-free interval following primary treatment).

Recognising this state changes the treatment philosophy from purely palliative care to an approach aiming for long-term control or extended remission. Instead of relying solely on medications to slow cancer progression, teams can incorporate aggressive local treatments. For eligible patients, eradicating every visible tumour site can delay cancer progression, prolong survival, and postpone the need to switch to harsher systemic therapies.

There is no single blood biomarker for oligometastatic disease. Accurate identification requires high-resolution staging with whole-body PET-CT scans, dedicated contrast-enhanced CT, and MRI (especially of the liver and brain). Liquid biopsies monitoring circulating tumour DNA are increasingly studied to evaluate overall microscopic disease burden.

Oligometastatic presentation occurs in many solid tumours. It is particularly common in colorectal cancer (frequently spreading to a few isolated liver or lung spots), non-small cell lung cancer, prostate cancer, breast cancer, and renal cell carcinoma. It may also be identified in melanoma and sarcoma.

Management typically combines systemic therapies (such as chemotherapy, immunotherapy, or hormone therapy) with ablative local therapies directed at all metastatic sites. These local treatments include stereotactic body radiation therapy (SBRT), surgical resection (such as hepatic metastectomy), or thermal ablation (radiofrequency or microwave ablation).